MedTrace Logo

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

NCT06862856 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-05-15

No results posted yet for this study

Summary

The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.

Conditions

  • Prostate Cancer (Adenocarcinoma)
  • Prostate Specific Antigen

Interventions

DIAGNOSTIC_TEST

Positron Emission Tomography (PET)

This is a PET scan with flotufolastat F 18 injection.

Sponsors & Collaborators

Principal Investigators

  • Jason Efstathiou, MD, DPhil · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-20
Primary Completion
2026-01-16
Completion
2026-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06862856 on ClinicalTrials.gov